메뉴 건너뛰기




Volumn 117, Issue 6, 1999, Pages 1485-1488

New life in a sleeper: Thalidomide and Crohn's disease

Author keywords

[No Author keywords available]

Indexed keywords

THALIDOMIDE;

EID: 0032732395     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0016-5085(99)70299-4     Document Type: Editorial
Times cited : (33)

References (32)
  • 1
    • 85119556944 scopus 로고    scopus 로고
    • Historical perspective.
    • FO. Kelsey Historical perspective. Thalidomide: potential benefits and risk. Open Public Scientific Workshop September 9, 1997 National Institutes of Health, Food and Drug Administration, Centers for Disease Control and Prevention Bethesda, MD
    • (1997)
    • Kelsey, FO.1
  • 2
    • 85119556212 scopus 로고    scopus 로고
    • Characterization of embryopathy risks.
    • BA. Hill Characterization of embryopathy risks. Thalidomide: potential benefits and risk. Open Public Scientific Workshop September 9, 1997 National Institutes of Health, Food and Drug Administration, Centers for Disease Control and Prevention Bethesda, MD
    • (1997)
    • Hill, BA.1
  • 3
    • 0027304271 scopus 로고
    • The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum
    • EP Sampaio G Kaplan A Miranda JA Nery CP Miguel SM Viana EN. Sarno The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum J Infect Dis 168 1993 408 414
    • (1993) J Infect Dis , vol.168 , pp. 408-414
    • Sampaio, EP1    Kaplan, G2    Miranda, A3    Nery, JA4    Miguel, CP5    Viana, SM6    Sarno, EN.7
  • 4
    • 85119557787 scopus 로고    scopus 로고
    • Current issues and overview.
    • J. Woodcock Current issues and overview. Thalidomide: potential benefits and risk. Open Public Scientific Workshop September 9, 1997 National Institutes of Health, Food and Drug Administration, Centers for Disease Control and Prevention Bethesda, MD
    • (1997)
    • Woodcock, J.1
  • 7
    • 0031937242 scopus 로고    scopus 로고
    • Recalcitrant pyoderma gangrenosum: treatment with thalidomide
    • MS Hecker MG. Lebwohl Recalcitrant pyoderma gangrenosum: treatment with thalidomide J Am Acad Dermatol 38 1998 490 491
    • (1998) J Am Acad Dermatol , vol.38 , pp. 490-491
    • Hecker, MS1    Lebwohl, MG.2
  • 9
    • 0027441787 scopus 로고
    • Chronic cutaneous lupus erythematosus treated with thalidomide
    • AL Holm KE Bowers TO McMeekin AA. Gaspari Chronic cutaneous lupus erythematosus treated with thalidomide Arch Dermatol 129 1993 1548 1550
    • (1993) Arch Dermatol , vol.129 , pp. 1548-1550
    • Holm, AL1    Bowers, KE2    McMeekin, TO3    Gaspari, AA.4
  • 10
    • 0028879351 scopus 로고
    • Prurigo nodularis and photosensitivity in AIDS: treatment with thalidomide
    • TG Berger C Hoffman MD. Thieberg Prurigo nodularis and photosensitivity in AIDS: treatment with thalidomide J Am Acad Dermatol 33 1995 837 838
    • (1995) J Am Acad Dermatol , vol.33 , pp. 837-838
    • Berger, TG1    Hoffman, C2    Thieberg, MD.3
  • 11
    • 0030942835 scopus 로고    scopus 로고
    • A prospective trial of thalidomide for the treatment of HIV-associated idiopathic esophageal ulcers
    • LN Alexander CM. Wilcox A prospective trial of thalidomide for the treatment of HIV-associated idiopathic esophageal ulcers AIDS Res Hum Retroviruses 13 1997 301 304
    • (1997) AIDS Res Hum Retroviruses , vol.13 , pp. 301-304
    • Alexander, LN1    Wilcox, CM.2
  • 13
    • 0029811736 scopus 로고    scopus 로고
    • Regression of AIDS-related Kaposi's sarcoma during therapy with thalidomide [discussion 504–505]
    • RA Soler M Howard NS Brink D Gibb RS Tedder D Nadal Regression of AIDS-related Kaposi's sarcoma during therapy with thalidomide [discussion 504–505] Clin Infect Dis 23 1996 501 503
    • (1996) Clin Infect Dis , vol.23 , pp. 501-503
    • Soler, RA1    Howard, M2    Brink, NS3    Gibb, D4    Tedder, RS5    Nadal, D6
  • 15
    • 0032943707 scopus 로고    scopus 로고
    • New chemotherapy options for the treatment of malignant gliomas
    • E Burton M. Prados New chemotherapy options for the treatment of malignant gliomas Curr Opin Oncol 11 1999 157 161
    • (1999) Curr Opin Oncol , vol.11 , pp. 157-161
    • Burton, E1    Prados, M.2
  • 16
    • 0031583764 scopus 로고    scopus 로고
    • Thalidomide in Crohn's disease
    • AR Wettstein AP. Meagher Thalidomide in Crohn's disease Lancet 350 1997 1445 1446
    • (1997) Lancet , vol.350 , pp. 1445-1446
    • Wettstein, AR1    Meagher, AP.2
  • 18
    • 0026080801 scopus 로고
    • Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes
    • EP Sampaio EN Sarno R Galilly ZA Cohn G. Kaplan Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes J Exp Med 173 1991 699 703
    • (1991) J Exp Med , vol.173 , pp. 699-703
    • Sampaio, EP1    Sarno, EN2    Galilly, R3    Cohn, ZA4    Kaplan, G.5
  • 23
    • 0032714591 scopus 로고    scopus 로고
    • Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial
    • ED Ehrenpreis SV Kane LB Cohen RD Cohen SB. Hanauer Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial Gastroenterology 117 1999 1271 1277
    • (1999) Gastroenterology , vol.117 , pp. 1271-1277
    • Ehrenpreis, ED1    Kane, SV2    Cohen, LB3    Cohen, RD4    Hanauer, SB.5
  • 24
    • 0029004771 scopus 로고
    • Chimeric anti-TNF monoclonal antibody cA2 binds recombinant transmem-brane TNF-alpha and activates immune effector functions
    • BJ Scallon MA Moore H Trinh DM Knight J. Ghrayeb Chimeric anti-TNF monoclonal antibody cA2 binds recombinant transmem-brane TNF-alpha and activates immune effector functions Cytokine 7 1995 251 259
    • (1995) Cytokine , vol.7 , pp. 251-259
    • Scallon, BJ1    Moore, MA2    Trinh, H3    Knight, DM4    Ghrayeb, J.5
  • 25
    • 0027230553 scopus 로고
    • Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation
    • AL Moreira EP Sampaio A Zmuidzinas P Frindt KA Smith G. Kaplan Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation J Exp Med 177 1993 1675 1680
    • (1993) J Exp Med , vol.177 , pp. 1675-1680
    • Moreira, AL1    Sampaio, EP2    Zmuidzinas, A3    Frindt, P4    Smith, KA5    Kaplan, G.6
  • 27
    • 0030851993 scopus 로고    scopus 로고
    • Thalidomide may impede cell migration in primates by down-regulating integrin beta-chains: potential therapeutic utility in solid malignancies, proliferative retinopathy, inflammatory disorders, neointimal hyperplasia, and osteoporosis
    • MF. McCarty Thalidomide may impede cell migration in primates by down-regulating integrin beta-chains: potential therapeutic utility in solid malignancies, proliferative retinopathy, inflammatory disorders, neointimal hyperplasia, and osteoporosis Med Hypotheses 49 1997 123 131
    • (1997) Med Hypotheses , vol.49 , pp. 123-131
    • McCarty, MF.1
  • 28
    • 0033021866 scopus 로고    scopus 로고
    • Protein kinase C–dependent effects on leukocyte migration of thalidomide
    • C Meierhofer S Dunzendorfer CJ Wiedermann Protein kinase C–dependent effects on leukocyte migration of thalidomide J Infect Dis 180 1999 216 219
    • (1999) J Infect Dis , vol.180 , pp. 216-219
    • Meierhofer, C1    Dunzendorfer, S2    Wiedermann, CJ3
  • 30
    • 0032922147 scopus 로고    scopus 로고
    • S.T.E.P.S.: a comprehensive program for controlling and monitoring access to thalidomide
    • JB Zeldis BA Williams SD Thomas ME. Elsayed S.T.E.P.S.: a comprehensive program for controlling and monitoring access to thalidomide Clin Ther 21 1999 319 330
    • (1999) Clin Ther , vol.21 , pp. 319-330
    • Zeldis, JB1    Williams, BA2    Thomas, SD3    Elsayed, ME.4
  • 31
    • 85119558793 scopus 로고    scopus 로고
    • Preventing birth defects due to thalidomide exposure.
    • AA. Mitchell Preventing birth defects due to thalidomide exposure. Thalidomide: potential benefits and risk. Open Public Scientific Workshop September 9, 1997 National Institutes of Health, Food and Drug Administration, Centers for Disease Control and Prevention Bethesda, MD
    • (1997)
    • Mitchell, AA.1
  • 32
    • 0027979817 scopus 로고
    • Thalidomide neuropathy incidence and clinico-electrophysiologic findings in 42 patients
    • S Ochonisky J Verroust S Bastuji-Garin R Gherardi J. Revuz Thalidomide neuropathy incidence and clinico-electrophysiologic findings in 42 patients Arch Dermatol 130 1994 66 69
    • (1994) Arch Dermatol , vol.130 , pp. 66-69
    • Ochonisky, S1    Verroust, J2    Bastuji-Garin, S3    Gherardi, R4    Revuz, J.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.